Guardant Health, Inc.
Clinical trials sponsored by Guardant Health, Inc., explained in plain language.
Precision oncology company developing liquid biopsy tests for cancer detection and monitoring.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Blood test aims to catch lung cancer before it spreads Results expected Dec 2026 (estimated)
-
Blood test aims to catch lung cancer before it spreads
Diagnosis OngoingThis study is testing a new blood test (GuardantLUNAR-2) to see how well it can detect lung cancer in people at high risk. About 12,000 smokers aged 50-80 will give a blood sample before their regular low-dose CT scan. The goal is to find out if the blood test is accurate enough …
Sponsor: Guardant Health, Inc. • Aim: Diagnosis
Last updated Jul 08, 2026 00:00 UTC
-
Blood test could revolutionize colon cancer screening
Diagnosis OngoingThis study is testing a new blood test called LUNAR-2 that looks for DNA from colorectal cancer in the bloodstream. It involves over 44,000 average-risk adults aged 45-84 who are already scheduled for a screening colonoscopy. The goal is to see how well this blood test can detect…
Sponsor: Guardant Health, Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC